Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: HylaCare, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rosacea
Interventions: Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Plaque Psoriasis
Interventions: roflumilast cream 0.3%, Zoryve, Placebo; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Oral Lichen Planus
Interventions: Pimecrolimus 1% cream; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Actinic Keratosis
Interventions: Aldara (imiquimod 5% cream), Vehicle cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Actinic Keratoses
Interventions: imiquimod cream, 3.75%, Vehicle Cream; Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more

Conditions: Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions: Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream); Drug
Lead sponsor: Center for Vulvovaginal Disorders; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Tampa, Florida • New York, New York

Conditions: Vitiligo
Interventions: ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment; Drug · Device
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 5
States / cities: San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more

Conditions: Allergic Contact Dermatitis
Interventions: EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%; Drug
Lead sponsor: Edesa Biotech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 14
States / cities: Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more

Conditions: Acne Vulgaris
Interventions: Visonac PDT (MAL PDT), Vehicle cream (placebo), PDT; Drug · Procedure
Lead sponsor: Photocure; Industry
Eligibility: 9 Years to 35 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Naperville, Illinois + 5 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 476 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Chronic Plaque Psoriasis
Interventions: E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more

Conditions: Tinea Pedis, Athlete's Foot
Interventions: Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%, Placebo Cream; Drug · Other
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Fremont, California • Hockessin, Delaware • Boca Raton, Florida + 9 more

Conditions: Atopic Dermatitis
Interventions: SB414 2%, SB414 6%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more

Conditions: Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
Interventions: AM001 Cream, 7.5%, Placebo of AM001 Cream; Drug
Lead sponsor: AmDerma; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico + 2 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more

Conditions: Atopic Dermatitis
Interventions: PF-06700841, Vehicle (Placebo); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more

Conditions: Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions: 5-fluorouracil, Placebo, vehicle control; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Head Lice
Interventions: 0.5% Ivermectin Cream, Placebo control; Drug
Lead sponsor: Topaz Pharmaceuticals Inc; Industry
Eligibility: 5 Months and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 7
States / cities: Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more

Conditions: Atopic Dermatitis
Interventions: Combination of pimecrolimus and fluticasone, pimecrolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Houston, Texas

Conditions: Acne Vulgaris
Interventions: Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more

Search by objective public record fields.

HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

Pimecrolimus Cream for Oral Lichen Planus

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Topical Ketotifen 0.25% for Secondary Vestibulodynia

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

Combination Therapy for Atopic Dermatitis

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)